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MiR expression proﬁles of paired primary colorectal cancer
and metastases by next-generation sequencing
M Neerincx1, DLS Sie2, MA van de Wiel3,4, NCT van Grieken2, JD Burggraaf5, H Dekker1, PP Eijk2, B Ylstra2, C Verhoef6, GA Meijer2,7,
TE Buffart1 and HMW Verheul1
MicroRNAs (miRs) have been recognized as promising biomarkers. It is unknown to what extent tumor-derived miRs are
differentially expressed between primary colorectal cancers (pCRCs) and metastatic lesions, and to what extent the expression
proﬁles of tumor tissue differ from the surrounding normal tissue. Next-generation sequencing (NGS) of 220 fresh-frozen samples,
including paired primary and metastatic tumor tissue and non-tumorous tissue from 38 patients, revealed expression of 2245
known unique mature miRs and 515 novel candidate miRs. Unsupervised clustering of miR expression proﬁles of pCRC tissue with
paired metastases did not separate the two entities, whereas unsupervised clustering of miR expression proﬁles of pCRC with
normal colorectal mucosa demonstrated complete separation of the tumor samples from their paired normal mucosa. Two
hundred and twenty-two miRs differentiated both pCRC and metastases from normal tissue samples (false discovery rate (FDR)
o0.05). The highest expressed tumor-speciﬁc miRs were miR-21 and miR-92a, both previously described to be involved in CRC with
potential as circulating biomarker for early detection. Only eight miRs, 0.5% of the analysed miR transcriptome, were differentially
expressed between pCRC and the corresponding metastases (FDR o0.1), consisting of ﬁve known miRs (miR-320b, miR-320d,
miR-3117, miR-1246 and miR-663b) and three novel candidate miRs (chr 1-2552-5p, chr 8-20656-5p and chr 10-25333-3p). These
results indicate that previously unrecognized candidate miRs expressed in advanced CRC were identiﬁed using NGS. In addition,
miR expression proﬁles of pCRC and metastatic lesions are highly comparable and may be of similar predictive value for prognosis
or response to treatment in patients with advanced CRC.
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INTRODUCTION
The majority of patients with colorectal cancer (CRC) die as a
consequence of metastatic disease.1 For patients with metastatic CRC
(mCRC) combination chemotherapy with 5-ﬂuorouracil, oxaliplatin or
irinotecan and anti-vascular endothelial growth factor or anti-
epidermal growth factor receptor monoclonal antibodies are
available.2 However, 10%–25% of patients do not beneﬁt from ﬁrst-
line treatment, with subsequent treatment regimens being even less
effective.3–5 There is an urgent clinical need to develop accurate
biomarkers to predict prognosis and treatment outcome of individual
patients with mCRC. Currently, RAS-oncogene-testing is the only used
clinical predictive molecular test for treatment of patients with
mCRC.6,7 Primary tumor analyses are predominantly being performed
for genomic proﬁling, but as genomic instability is a hallmark of
cancer, the genomic make-up of primary tumors and their metastases
may deviate over time. In addition, adaptation of metastasized tumor
cells to their speciﬁc microenvironment may lead to selection and
expansion of speciﬁc clones with distinct molecular characteristics
compared with the primary tumor. In previous studies, conﬂicting
results of the genomic characteristics of both primary CRC (pCRC) and
metastases from the same patients were found, varying from an
almost identical make-up8–11 to clear differences.12,13
Small non-coding microRNAs (miRs) are attractive candidates to
serve as biomarkers, because they display speciﬁc expression
patterns and can be detected in tissues as well as in the circulating
blood, as they are relatively resistant to degradation.14–17 Recent
data indicate that speciﬁc miRs have prognostic and predictive
value for patients with CRC.18,19 However, it is estimated that more
than a third of the miRs of most cellular types are still unknown
and a comprehensive comparison of miR expression proﬁles in
mCRC is currently lacking.20
In this study, miR expression proﬁles of mCRC were robustly
characterized with next-generation sequencing (NGS). Proﬁles of
pCRC tissue and metastases from the same patients were
compared, to identify whether miR expression proﬁles differ
between pCRC and metastases. In addition, proﬁles of tumor
tissue were compared with corresponding normal tissue, to
identify tumor-speciﬁc miRs. By elucidating the miR transcriptome
of mCRC, this study provides a framework for the development of
miR-based biomarkers for patients with mCRC.
RESULTS
The miR transcriptome of advanced CRC: identiﬁcation of known
and novel candidate miRs
NGS of the miR transcriptome of 220 tissue samples yielded
2 176 783 818 raw reads. Samples consisted of 126 pCRC tissue
samples from patients with advanced CRC, 54 paired metastases
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(M), 23 paired samples with normal colorectal mucosa (PN) and 17
paired samples with normal extra-colonic tissue (MN). As
demonstrated by sample M15, increasing the number of reads
above ~ 10 million reads per sample did not result in a meaningful
increase in the number of unique miRs (Figure 1a). Based on
these ﬁndings, measuring ~ 10 million reads per sample was
considered to be sufﬁcient to analyze the miR transcriptome of
mCRC, which is supported by the resulting data points from the
complete study (Figure 1a). The data yield per sample ranged from
4 690 871 to 74 313 067 reads per sample with a mean of
9 894 472 reads (Figure 1b). After adapter and quality trimming,
99.5% (2 165 268 282) of initial raw reads was retained. The read
length distribution after adapter and quality trimming is shown in
Figure 1c. Reads of at least 18 nt, which could be mapped to the
reference genome with ⩽ 2 mismatches, were used for the
identiﬁcation and quantiﬁcation of the miR transcriptome
of mCRC.
In total, 2760 unique miR sequences were observed, repre-
sented by 1 141 450 029 read counts. Five hundred and ﬁfteen
sequences represented candidate novel mature miRs and 2245
sequences corresponded to known mature miRs included in
miRbase 19 (Figure 2a). The distribution of the log2 expression
levels of the 2760 miR sequences is shown in Figure 2b. Candidate
novel miRs represented 1 567 621 read counts in total (range:
1–350 911; 0.14%) and known miRs represented 1 139 882 408
read counts in total (range: 1–197 979 477; 99.86%). Of the 2760
miRs, 585 miRs were expressed in ⩾ 90% of the samples and 977
miRs were expressed in ⩽ 10% of the samples (Figure 2c). The
number of miRs expressed per sample ranged from 626 to 1710
(mean 1086). The 515 novel candidate miR sequences are listed in
Supplementary Table S1. These sequences were distributed
throughout the genome as illustrated by their chromosomal
localizations. Candidate sequences were located on all 23
chromosomes and ranged from 4 sequences on chromosome 21
to 41 sequences on chromosome 1 (Supplementary Table S1).
Reproducibility
To check the reproducibility of the workﬂow, two samples were
analyzed as biological triplicates and two samples were analyzed
as technical duplicates. The Spearman’s correlation of the miR
expression levels of the biological triplicates ranged from 0.91 to
0.99 and those of the technical duplicates ranged from 0.95 to
0.98, indicating that the workﬂow is highly reproducible.
MiR expression in primary CRCs and paired metastases
For the analysis of miR expression proﬁles of paired pCRCs and
metastases, 125 samples were used corresponding to 38
individual patients with CRC (Supplementary Table S2). Of the
total number of 2760 different miRs expressed in the whole data
set, 2635 miRs were found in these 125 samples, representing
607 569 807 read counts. Of those, 1714 miRs were expressed in at
least 3 of the 125 samples and were included for further analyses
(Figure 3).
Unsupervised clustering. Unsupervised clustering of log-
transformed normalized miR expression levels showed no clear
separation of pCRC tissue with paired metastases (Figure 4a). In
contrast, unsupervised clustering demonstrated complete separa-
tion of pCRC tissue from paired normal mucosa (Figure 4b).
Clustering of the metastases with their paired normal extra-colonic
tissue resulted in ﬁve distinct clusters. Two clusters contained only
metastases and two clusters contained only normal extra colonic
tissues. Normal lung epithelium (MN1, MN12_2 and MN32)
clustered separately from the other normal extra colonic tissue
samples. The ﬁfth cluster contained metastases and normal gastric
mucosa (MN11_2) (Figure 4c).
Figure 1. (a) Relationship between the numbers of raw sequence
reads per sample (x axis) and number of unique identiﬁed miRs per
sample (y axis) for 220 samples. Sample M15 was sequenced in
triplicate at different read depths. Increasing the read depth from
3.7 to 8.6 million reads identiﬁed 238 additional unique miRs (47.9
miRs per million additional reads). Increasing the read depth from
8.6 to 18.3 million reads identiﬁed 44 additional unique miRs (4.5
miRs per million additional reads). (b) NGS read depth for 220
samples. Samples are shown on the x axis and read depth is shown
on the y axis. Mean read depth achieved was 9.894.472 raw
sequence reads per sample (dotted line). (c) Length distribution of
the sequence reads after adapter and quality trimming in 220
samples. The x axis depicts the length of the sequence reads in
nucleotides. The y axis depicts the number of reads. The bars
represents the mean read count per length, the box represents the
upper and lower quantiles and the median. The two length peaks
represents the 20–24 nt and 31–34 nt small RNA fragments primarily
selected with Illumina’s TruSeq Small RNA Sample Preparation
protocol. Abbreviations: M, million; nt, nucleotides.
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Differential expression analysis. Paired analysis of normalized
expression levels of pCRC and corresponding metastatic lesions
(M–pCRC) yielded 37 out of 1714 miRs (2.2%) with signiﬁcant
different expression levels (false discovery rate (FDR) ⩽ 0.10). For
29 of these 37 miRs, the difference in expression level between
metastases and pCRC (|M–pCRC|) was not signiﬁcantly larger than
between normal extra-colonic tissue and normal colon mucosa
(|MN–PN|). Therefore, the observed difference between pCRC and
M was considered to be of tissue-speciﬁc origin rather than
metastases-speciﬁc differential expression. After exclusion of these
29 tissue-speciﬁc miRs, 8 miRs of the initial 1714 miRs (0.5%) were
expressed signiﬁcantly different between pCRCs and correspond-
ing metastases (Table 1). The eight miRs consisted of ﬁve known
miRs (miR-320b, miR-320d, miR-3117, miR-1246 and miR-663b)
and three novel candidate miRs (chr 1-2552-5p, chr 8-20656-5p
and chr 10-25333-3p). The novel candidate miRs are located on
1q42.13, 8p23.3 and 10q26.12 (Supplementary Table S1). Of the 8
miRs, miR-320b, miR-320d and miR-1246 were expressed in all 125
samples and were expressed signiﬁcantly higher in metastatic
lesion compared with those in pCRC tissue, whereas miR-3117,
miR-663b and 3 novel candidate miRs were expressed signiﬁcantly
higher in pCRC tissue compared with those in the metastatic
lesion (Table 1).
MiRs differentially expressed between tumor and normal tissue
Of the 1714 miRs, 222 miRs were concordantly differently
expressed between metastasis and normal extra-colonic tissue
(MN–M, FDR ⩽ 0.05) and between pCRC and normal colorectal
mucosa (PN–pCRC, FDR ⩽ 0.05). Those miRs distinguished pCRC
tissue and metastasis from normal tissue, and were considered
potentially useful in diagnostic tests as well as for early detection
Figure 2. (a) 2760 miRs were expressed in mCRC, including 515 novel candidate miRs (shown in gray) and 2245 miRs known from miRbase
v.19 (shown in white). (b) Log2 expression levels (x axis) of the 2760 mature miR sequences (y axis). Candidate miRs represented 1 567 621
reads in total (range: 1–350 911; 0.14%) and known miRs represented 1 139 882 408 reads in total (range: 1–197 979 477; 99.86%). Therefore,
the higher expression levels are dominated by known miRs, whereas the candidate miRs are expressed at lower levels. (c) Percentage of
samples (x axis) in which each miR is expressed (y axis). Nine hundred and seventy-seven miRs consisting of 217 candidate miRs and 760
known miRs were expressed in ⩽ 10% of the samples. Of those, 198 miRs were expressed in one sample. Five hundred and eighty-ﬁve miRs
consisting of 29 candidate miRs and 556 known miRs were expressed in ⩾ 90% of the samples. Of those, 291 miRs were expressed in all 220
samples.
Figure 3. Overview of the number of raw reads, the number of reads after adapter and quality trimming, and the number of reads of at least
18 nt, which could be mapped with a maximum of two mismatches to the reference genome (browser hg 19). 2760 miRs were represented by
1 141 450 029 read counts, of which 2635 miRs were detected in at least 1 of the 125 samples used for paired sample analysis and 1714 miRs
were detected in at least 3 of the 125 samples.
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Figure 4. (a) Unsupervised clustering of log-transformed normalized miR expression levels of primary CRC samples and paired metastases of
38 patients based on 1714 miRs. Samples are shown in columns. MiRs are shown in rows. Expression levels for each miR were scaled per miR
in red and blue. (b) Unsupervised clustering of primary CRC samples and normal colorectal epithelium. (c) Unsupervised clustering of
metastases and normal extra-colonic tissue.
MiR analysis of advanced colorectal cancer
M Neerincx et al
4
Oncogenesis (2015), 1 – 9
of recurrences. One hundred and thirty-ﬁve miRs were higher
expressed in the tumor tissue compared with those in the normal
tissue. Of those, 121 were known mature miRs and 14 were
potential novel candidate sequences (Supplementary Table S3). In
addition, 87 miRs were expressed signiﬁcantly lower in the tumor
tissue compared with those in the normal tissue. Of those, 86 were
already known mature miRs and 1 was a novel candidate
sequence (Supplementary Table S4). Chromosomal location,
nucleotide sequence and read count of the 15 novel candidate
miRs are included in Supplementary Table S1. Figure 5 shows the
correlation of the expression level fold change between MN and M
with those between PN and pCRC of the 222 tumor-speciﬁc miRs.
The upregulated tumor-speciﬁc miRs included miR-320b,
miR-320d and miR-1246. These miRs were also expressed
signiﬁcantly higher in metastatic tumor tissue compared with
those in pCRC tissue (Figure 5). MiR-21-5p and miR-92a were the
miRs with the highest expression in pCRC as well as in metastases.
Table 2 gives an overview of the upregulated tumor-speciﬁc miRs
in pCRC and metastases with an overall expression level of more
than 1000 (expressed as geometric mean expression level). These
miRs might be the most ideal candidates for use as biomarker in
clinical practice.
DISCUSSION
In this study it was demonstrated that the miR expression proﬁle
of metastases closely resembles that of their corresponding
pCRCs. Unsupervised cluster analysis of 40 pCRCs and 45
metastases did not separate pCRCs from their metastases. Only
8 (0.5%) of the 1714 miRs used for expression analysis were
expressed signiﬁcantly different between pCRC and metastases.
Based on these results, we expect that miR expression proﬁles can
be further developed as predictive biomarkers for prognosis and
response to treatment irrespective of a primary or secondary
origin of the CRC tissue. This is of clinical signiﬁcance, because
tissue samples from the primary tumor are often readily available,
while these are not routinely collected from metastases. There is
currently no consensus whether analysis of primary tumor tissue is
sufﬁcient when analyzing the mutational status of a
tumor.11,13,21,22 Therefore, the development of miR-based biomar-
kers can serve as an important alternative to mutation analysis in
the advanced setting.
The process of metastasis formation can be divided into speciﬁc
tumor cell characteristics as follows: (1) loss of cellular adhesion,
(2) increased invasiveness, (3) intravasation and survival in the
vascular system, (4) extravasation, and (5) survival and prolifera-
tion at a new site.23 MiRs have been described to have crucial roles
in acquiring these characteristics.14,24,25 and several hypotheses
have been proposed to explain how tumor cell populations evolve
to acquire them.26 Initially, the process of metastases has been
seen as the ﬁnal step in a sequential accumulation of (epi)genetic
alterations within the site of the primary tumor.23 In contrast, the
predestination model27 implies that the metastatic potential of
tumor cells is already determined relatively early in carcinogenesis
within the primary tumor and metastatic dissemination is not
solely placed at the end of pCRC progression. The initial model
and the predestination model both suggest minor genetic
differences between primary tumors and metastases. According
to a third model, parallel progression and evolution of primary
tumors and metastases may occur at different sites.28 This
implicates a greater disparity and variation of genetic proﬁles.
The small differences in miR expression signatures between pCRC
and metastases observed in this study suggest that the changes in
miR expression levels were already present in the primary tumors
and supports the predestination model.29 Of the eight
Table 1. Colorectal cancer metastases-speciﬁc miRs
miRNA Geometric meana M–pCRC MN–PN (|M–pCRC|–|MN–PN|)
M (n= 45) pCRC (n= 40) MN (n=17) PN (n=23) FDR Log fold change FDR Log fold change FDR Log fold change
hsa-miR-1246 293.0 (100) 79.0 (100) 67.9 (100) 56.7 (100) 0.017 0.84 0.032 − 0.91 0.000 2.32
hsa-miR-320b 330.0 (100) 220.0 (100) 202.0 (100) 214.0 (100) 0.043 0.45 0.112 − 0.16 0.002 0.80
hsa-miR-320d 41.0 (100) 27.0 (100) 20.9 (100) 20.7 (100) 0.091 0.40 0.277 − 0.07 0.005 0.82
hsa-chr1_2552-5p 1.6 (73) 1.8 (80) 2.5 (59) 3.8 (91) 0.035 − 0.41 0.490 0.06 0.046 − 0.85
hsa-miR-3117-3p 4.8 (84) 11.3 (98) 7.0 (88) 2.4 (83) 0.072 − 0.46 0.497 0.04 0.006 − 1.11
hsa-chr10_25333-3p 0.2 (18) 0.7 (60) 0.8 (59) 0.8 (65) 0.085 − 0.54 0.460 0.05 0.012 − 1.30
hsa-miR-663b 0.8 (49) 1.9 (88) 2.9 (65) 1.8 (70) 0.095 − 0.56 0.172 0.30 0.003 − 1.62
hsa-chr8_20656-5p 1.0 (56) 2.7 (93) 2.9 (65) 0.7 (57) 0.064 − 0.62 0.118 0.46 0.009 − 1.63
Abbreviations: FDR, false discovery rate; M, metastases; miR, microRNA; MN, normal extracolonic tissue; pCRC, primary colorectal cancer; PN, normal colorectal
mucosa. Fold change is noted as natural logarithm. FDR was estimated using the Bayesian FDR estimate. Overview of the eight metastases-speciﬁc miRs,
including the mean expression values, percentage of samples in which these miRs are expressed, FDRs and log fold changes. aExpression level is noted as
mean geometic value. In brackets are the percentage of samples that expressed the mature miR.
Figure 5. Correlation of expression level log fold change between
metastasis and normal extra-colonic tissue with those between
pCRC and normal colorectal mucosa of the 222 tumor-speciﬁc miRs.
MiR-21-5p and miR-92a were the miRs with the highest expression
in primary tumors as well as in metastases. The expression levels of
the metastases-speciﬁc miRs, miR-320b, miR-320d and miR-1246 are
shown in red.
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differentially expressed miRs, miR-320b, miR-320d and miR-1246
were expressed signiﬁcantly higher in the metastatic lesion
compared with those in pCRC, and miR-3117, miR-663b, chr
1-2552-5p, chr 8-20656-5p and chr 10-25333-3p were expressed
signiﬁcantly higher in pCRC compared with those in the
metastatic lesion. A role in CRC metastases formation has been
proposed for miR-320b, miR-320d and miR-1246.30–33 MiR-320b
was found to be upregulated in a recent study comparing miR
expression proﬁles of CRC patients with and without liver
metastasis.33 Overexpression of miR320b upregulates β-catenin
(CTNNB1), Neurophilin 1 (NRP1) and Ras-related C3 botulinum
toxin substrate (RAC1). Interestingly, these genes are known to
promote tumor metastasis.33 A role for miR-320d in the
proliferation of CRC is suggested by in situ hybridization of CRC
and normal colonic mucosa based on the ﬁnding that the highest
expression of miR-320d was found in CRC cells and in the
proliferative compartment of the colonic crypts of normal colonic
mucosa.30 This study also demonstrated that a higher expression
of miR-320d is associated with an increased recurrence free
survival of stage II CRC patients. In vitro, circulating miR-1246
secreted by CRC cells is associated with proliferation, migration
and tube formation of endothelial cells. Thereby, miR-1246 might
contribute to tumor angiogenesis.32 Downregulation of cell
adhesion molecule 1 by miR-1246 enhances migration and
invasion of hepatocellular carcinoma cell lines, further suggesting
a role of miR-1246 in tumor metastases formation.31 When these
miRs involved in the process of metastasis formation are further
validated, therapeutic strategies can be developed that aim at the
inhibition of the oncogenic miRs or reintroduction of the tumor-
suppressive miRs. The potential activity of using anti-miR
oligonucleotides as a therapeutic strategy is demonstrated in a
phase IIa trial for hepatitis C and is currently investigated for
patients with advanced CRC as well.34–36
The role of miR-3117, miR-663b and the three novel candidate
miRs on chr 1-2552-5p, chr 8-20656-5p and chr 10-25333-3p in the
metastasizing process is unknown and functional studies have not
been performed. In addition, the chromosomal locations 1q42.13,
8p23.3 and 10q26.12 on which the novel candidate miRs are
located, respectively, are not known to be involved in the
formation of metastases.
In this study, less differentially expressed miRs between pCRC
and metastases compared with previous studies were found.37–39
The design of the current study has several strengths. First, fresh-
frozen tissues of paired primary tumors and metastases were used.
Comparing the genetic proﬁle of metastases with unmatched
primary tumors is of limited value, owing to the heterogeneity in
miR expression levels between primary tumors.24 This is conﬁrmed
by the unsupervised clustering analysis, demonstrating a large
heterogeneity in miR expression levels between tumors of
different patients. Second, 89% of the tumor samples yielded a
tumor cell content of more than 70%, thereby minimizing the
inﬂuence of the expression of non-tumorous miRs. By including
the miR expression proﬁles of adjacent normal tissue in the
analysis as well, the inﬂuence of non-tumorous miRs on the
differential expression analysis between pCRC and metastases was
further minimized. Third, the amount of measured miRs was more
than doubled compared with previously published studies
identifying the miR transcriptome of CRC.40–42 Prior reports
comparing miR expression in mCRC used probe-based
methodologies,37–39 which, by deﬁnition, are restricted to the
detection and proﬁling of the known miR molecules. Recent
studies using NGS-based methodologies used sequencing depths
varying between one million and three million reads per
sample.42,43 However, the high dynamic expression range of miRs
can result in a proﬁle that is dominated by a few highly expressed
miRs, which makes it difﬁcult to detect low-expressed miRs.44,45
Therefore, the preferred read depth was ﬁrst identiﬁed at
~ 10 million reads per sample. Owing to the overrepresentation
of liver metastases compared with the other locations, it was not
possible to analyse whether the location of metastases had an
effect on differential expression; for example, whether there were
miR expression proﬁles speciﬁc for the location of the metastases.
Likewise, it was not possible to include the organ of metastasis for
the MN–PN comparison because of the overrepresentation of
normal epithelium of the liver. In addition, miRs that are not
phylogenetically conserved might have been missed by using
Table 2. Tumor-speciﬁc miRs with an overall expression of more than 1000 (expressed as geometric mean expression level) in pCRC and metastases
miRNA Geometric meana FDR Log fold change
M (n=45) MN (n=17) pCRC (n= 40) PN (n= 23) MN vs M PN vs pCRC MN vs M PN vs pCRC
hsa-miR-21-5p 256 999 156 999 232 999 128 999 0.0000 0.0000 − 1.18 − 0.79
hsa-miR-92a-3p 99 499 73 699 80 099 40 799 0.0006 0.0000 − 0.60 − 0.90
hsa-miR-182-5p 36 199 9599 29 399 9189 0.0000 0.0000 − 2.29 − 1.28
hsa-miR-21-3p 14 899 8409 13 099 5049 0.0000 0.0000 − 1.10 − 1.11
hsa-miR-25-3p 10 099 8349 9449 6099 0.0148 0.0000 − 0.37 − 0.46
hsa-miR-93-5p 6199 4159 5359 3809 0.0000 0.0000 − 0.96 − 0.53
hsa-miR-98-5p 5709 4489 6519 4219 0.0013 0.0408 − 0.63 − 0.26
hsa-miR-183-5p 3919 980 4259 842 0.0000 0.0000 − 2.66 − 1.42
hsa-miR-181c-5p 3839 2649 3109 2519 0.0007 0.0004 − 0.91 − 0.54
hsa-miR-19b-3p 3819 2739 2679 1859 0.0021 0.0002 − 0.69 − 0.65
hsa-miR-20a-5p 3629 2439 3069 1829 0.0000 0.0000 − 1.02 − 0.88
hsa-miR-92b-3p 3529 2329 5749 3049 0.0156 0.0166 − 0.65 − 0.39
hsa-miR-23a-3p 3519 2829 3419 2859 0.0036 0.0191 − 0.58 − 0.24
hsa-miR-222-3p 3419 1809 3609 2429 0.0011 0.0012 − 0.99 − 0.44
hsa-miR-532-5p 2819 1769 2389 1719 0.0000 0.0119 − 0.83 − 0.36
hsa-miR-17-5p 2549 1599 2139 1139 0.0000 0.0000 − 1.12 − 0.92
hsa-miR-335-3p 1679 1079 1809 695 0.0000 0.0000 − 1.15 − 1.04
hsa-miR-941 1539 1029 1749 923 0.0000 0.0189 − 0.92 − 0.45
Abbreviations: FDR, false discovery rate; M, metastases; miR, microRNA; MN, normal extracolonic tissue; pCRC, primary colorectal cancer; PN, normal colorectal
mucosa. MiRs were higher expressed in both pCRC and metastases compared with normal adjacent tissue. aExpression level is noted as mean geometic value.
Fold change is noted as natural logarithm. FDR was estimated using the Bayesian FDR estimate.
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miRdeep2 as prediction algorithm to identify novel candidate miR
sequences.
In contrast to the minor differences observed between pCRC
and metastatic tumor tissue, 222 tumor-speciﬁc miRs were
observed with a signiﬁcantly different expression proﬁle in both
pCRC as well as metastases compared with its adjacent normal
tissue. We hypothesize that upregulated tumor-speciﬁc miRs
might yield the potential to assist in early detection or recurrence
of pCRC or distant CRC metastases by measuring the circulating
levels of these miRs. Mitchell et al.17 were the ﬁrst to demonstrate
that tumor-derived circulating miRs had the potential to detect
solid cancers and blood-based miR proﬁles speciﬁc for cancers
and non-cancer diseases have been established since.46 MiR-21
and miR-92a were the two highest expressed discriminatory miRs
in the current study. Strikingly, these two miRs were recently
identiﬁed for having potential as circulating biomarker for early
detection and screening of CRC.47–50 Furthermore, both miR-92a
and miR-21expression were shown to correlate with mCRC and
regulate invasion and metastases by inhibiting phosphatase and
tensin homolog.51–53 Five metastases-speciﬁc miRs were not
represented in the 222 tumor-speciﬁc miRs, because for those
miRs the difference in expression level between tumor tissue and
adjacent normal tissue was not signiﬁcant for both pCRC and
metastases.
In summary, NGS was used to analyze miR expression proﬁles of
mCRC including both known and novel candidate miRs. MiR
expression proﬁles of pCRC and metastases were highly compar-
able and may therefore be of similar predictive value for prognosis
or treatment response for patients with mCRC. We foresee that in
the coming years detection of speciﬁc low-abundant miRs might
be performed using targeted sequencing, looking in depth at the
expression level of a selected number of miRs. This increased
sensitivity will make it possible to include important discrimina-
tory low-abundant miRs in a prediction algorithm to select
patients in clinical practice.
MATERIALS AND METHODS
Patients and tumor samples
Two hundred and twenty fresh-frozen tissue samples resected between
1997 and 2012 were collected, to characterize the miR transcriptome of
mCRC. Samples consisted of 126 pCRC tissues samples, 54 metastases (M),
23 samples with normal colorectal mucosa (PN) and 17 samples with
normal extra-colonic tissue (MN). The metastatic tissue specimens
consisted of 23 liver, 5 lung, 6 ovarian and 9 peritoneal metastases, and
9 metastases in the distant lymph nodes, 1 metastasis in the stomach and
1 in the thoracic wall. Samples were collected from the archives of the VU
University Medical Center of Amsterdam, the Spaarne Hospital of
Hoofddorp and the Erasmus University Medical Center of Rotterdam,
according to the ethical guidelines of these hospitals. Samples from
patients with neoadjuvant radiotherapy or systemic therapy within
6 months before resection of the primary tumor were excluded.
Samples included 125 paired tissue samples of 38 consecutive patients
of which pCRC tissue samples as well as corresponding synchronous or
metachronous metastases were directly frozen after surgery. An overview
of tumor and patient characteristics of the paired tissue samples is given in
Supplementary Table S2. The paired tissue samples consisted of 40 pCRC
samples, 45 metastases, 23 samples with normal colorectal mucosa and 17
samples with normal extra-colonic tissue. Two pCRC samples were
microsatellite instable. The metastatic tissue specimens consisted of 20
liver, 4 lung, 6 ovarian and 5 peritoneal metastases, and 8 metastases in
the distant lymph nodes. One metastasis was located in the stomach and 1
in the thoracic wall. The normal extra-colonic tissue samples included 12
samples with liver tissue, 3 samples with lung tissue, 1 sample with ovarian
tissue and 1 sample with gastric mucosa. From seven patients two
different metastatic localizations were included and from one patient two
independent primary tumors were included. From one patient, material
from the original tumor was lacking and tumor material of the local
recurrence was used instead. From another patient, material from the
primary tumor, the local recurrence and the metastatic lesion was
included. In 12 cases, systemic therapy was given between resection of
the primary tumor and the subsequent resection of a metastasis, and 4
cases were within 6 months before resection of the metastases. All tumors
were classiﬁed according to the WHO classiﬁcation for colorectal
carcinomas.54 Normal colorectal mucosa and normal extra-colonic tissues
were histologically classiﬁed as cancer-free.
RNA isolation
Four-micrometer sections were made of each tumor sample, stained with
hematoxylin and eosin and evaluated by a gastro-intestinal (GI) pathologist
(NCTvG or GAM). Tumor areas with the highest tumor cell density were
selected and the remaining tissue was macrodissected and removed from
the tissue specimen. A new 4-μm hematoxylin and eosin section was made
and evaluated for tumor cell content. Macrodissection was repeated until
the tumor cell density could not be further improved. After macrodissec-
tion, 10–40 (depending on the tumor surface area) 25 μm slides were cut
and directly frozen in the liquid nitrogen. Sandwich hematoxylin and eosin
sections were made and independently evaluated for tumor content. Of all
180 tumor samples (126 primary tumors and 54 metastases), 160 (89%)
yielded at least 70% tumor cells. The 20 tumor samples containing o70%
tumor cells (range: 35%–65%) were all classiﬁed as mucinous tumors or
showed a high percentage of inﬂammatory cells. Of the 85 paired tumor
samples (40 pCRC samples and 45 metastases) used for the miR expression
analysis between primary tumors and metastases, 74 (87%) contained at
least 70% tumor cells (Supplementary Table S2). Sandwich hematoxylin
and eosin slides of the normal tissue samples were classiﬁed as 100%
cancer free. Total RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA,
USA) and RNA quantity was determined with a Nanodrop 2000 (Thermo
Scientiﬁc, Waltham, MA, USA). To optimize the isolation of small RNA
species, isopropanol volume was 50% increased and 75% ethanol was
used two times as wash solution.
Next-generation sequencing
Illumina’s TruSeq Small RNA Sample Preparation protocol (Illumina Inc., San
Diego, CA, USA) was used to prepare the cDNA libraries with 1 μg RNA
input. Forty-eight unique barcode sequences were applied for simulta-
neous analysis of multiple samples. Sequence library yield was assessed
using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA) with DNA1000 chips before sequencing. The library was loaded onto
an Illumina cluster station (Illumina Inc., San Diego, CA, USA) and
sequenced using Illumina’s High Seq 2000 (Illumina Inc., San Diego, CA,
USA). The optimal read depth to analyse the miR transcriptome of CRC
tissue was determined at 10 million reads per sample (Figure 1a).
Data ﬁltering
Several data ﬁltering steps were performed after obtaining the raw reads.
First, the FASTQ Quality Trimmer (http://hannonlab.cshl.edu/fastx_toolkit)
was applied to trim the 3′-end of the reads from nucleotides with a Phred-
scaled quality score below 30, corresponding to a499.9% probability of a
correctly identiﬁed base. Second, the 3′-ends of the reads were clipped for
adaptor sequences. Third, reads with identical sequences were counted
and collapsed resulting in only unique sequences to reduce the storage
and computation requirements. Finally, each unique sequence was
mapped to the reference genome (browser hg19) and alignments of at
least 18 nt and a maximum of 2 mismatches were retained. Genome data
have been deposited at the European Genome-phenome Archive (http://
www.ebi.ac.uk/ega/), which is hosted at the European Bioinformatics
Institute (EBI), under accession number EGAS00001001127.
Identiﬁcation of novel candidate miRs
The miRDeep2 package was used to identify novel candidate miRs in the
obtained deep sequencing data,55 as this method was found to be most
suitable for identifying novel miR candidates.56 This package uses a
probabilistic model of miR biogenesis to score compatibility of the position
and frequency of sequenced RNA with the secondary structure of the miR
precursor.55 The majority of miRs are transcribed as long primary
transcripts from which one or more ~ 70-nt-long hairpin precursors (pre-
miRs) are cleaved out by the Drosha endonuclease.57 Therefore, for each
read, potential precursor sequences were retrieved from both genome
contigs, one including 70 nt upstream and 20 nt downstream ﬂanking
sequence, and one including 20 nt upstream and 70 nt downstream
ﬂanking sequence. For each candidate pre-miR sequence, the potential
secondary structure was predicted. Based on those predicted secondary
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structures of the potential precursor sequences, the thermodynamic
energy to fold these precursors and the conservation among three species
(chimpanzee, mouse and rat), predictions for each sequence read were
made. The presence of multiple sequenced RNAs corresponding to the
mature miR, the presence of the complementary strand of the mature miR
and the presence of the loop of the precursor in the sequencing data were
used as a support to identify a sequence as novel candidate miR. Reads
from all 220 samples were pooled during the identiﬁcation of known and
novel miRs, as novel candidate miRs can be more accurately predicted by
detecting both the − 5p and –3p sequences in multiple independent
samples. In order to exclude sequences originating from repetitive
elements, reads that aligned to more than ﬁve positions in the genome
were excluded from further analysis. In addition, sequences that could be
mapped to other known non-coding RNAs or sequences within coding
regions were excluded. For each analysis, the lowest cutoff score that
yielded a signal-to-noise ratio of 5:1 or higher was used (Friedlander,
personal correspondence). The signal-to-noise ratio was estimated as the
number of total miRs (novel candidate miRs and known miRbase v.19
miRs) divided by the estimated total number of false-positive novel
candidate miRs. The number of false positives was calculated for a given
cutoff point by permutation.
Quantiﬁcation of the miR transcriptome of mCRC
Sequencing reads were quantiﬁed by mapping them against precursor
sequences from mirbase v.19 and the novel predicted precursor sequences
resulting from the miRDeep2 analyses. A sequencing read (up to one
mismatch was allowed) was assumed to represent a sequenced mature
miR if it aligned within the same position on the precursors as the known
or predicted mature –3p or –5p sequence (no mismatch was allowed). A
small window of 2 nt upstream and 5 nt downstream around the
annotated mature miR in its precursor was allowed, because sequencing
reads originating from true miRs can be subjected to untemplated
nucleotide addition and inaccurate Dicer processing. Reads that map
equally well to the positions of multiple mature miRs were added to the
read counts of those mature miRs. However, miRs mapping to an unrelated
precursor were removed from further analysis. Read counts of identical
mature miRs mapping to related precursors (for example, hsa-mir-7-1, hsa-
mir-7-2 and hsa-mir-7-3) were averaged.
Statistical analysis
Unsupervised clustering and pair-wise comparisons were performed on
miRs with expression in at least three samples. Normalization was done
using edgeRs TMM method.58 Unsupervised clustering was done using
Euclidean distance between the log2 of normalized expression levels and
using Ward’s minimum variance linkage across samples. The cluster
analysis was performed in R using the gplots package, version 2.16.0. Pair-
wise comparisons were performed using the R-package ShrinkBayes,
version 2.8,59 which is accessible on http://www.few.vu.nl/ ~mavdwiel/
ShrinkBayes.html. To account for multiple testing, an FDR was estimated
using the Bayesian FDR estimate.60 The mean expression value was
expressed as a geometric mean value, which is a conventional summary
for (skewed) count data. For the comparison of pCRC with metastases,
miRs were selected to be signiﬁcantly differentially expressed if FDR ⩽ 0.10.
Compared with the analysis of tumor-speciﬁc miRs, a less strict FDR for
these comparisons was used to decrease the number of false-negative
miRs. To correct for miR expression in non-tumorous tissue, it was
determined whether the difference in expression level between pCRC and
M was signiﬁcantly larger (one sided test) than between normal colorectal
mucosa (PN) and normal tissue of the organ of metastases (MN). To
account for potential confounders on differences in miR expression, the
following additional covariates in the regression models were included:
organ of metastasis, time between the resection of pCRC tissue and the
metastatic tissue, and the use of chemotherapy in the time period
between the resections. If the time between resection of pCRC and
metastases was o90 days, or if the metastases were resected before
resection of the pCRC, this pair of tumor tissue was considered to be
synchronously metastasized (no time between the resections). If a patient
had two pCRCs, the mean time between the resections of those pCRCs
with the metastasis was used for analysis. If a patient had two metastases
resected, both paired comparisons were included. Organ of metastasis was
only included as a covariate for the M–pCRC comparison and not for the
MN–PN comparison, because normal epithelium of the liver was over-
represented compared with the other organs.
To determine which miRs were tumor speciﬁc, it was analyzed which
miRs were differently expressed between M and MN samples, and were
concordantly differentially expressed between pCRC and PN samples.
Given the large number of differential miRs for these comparisons, a more
restrictive FDR cutoff was used to minimize the number of false-positive
miRs (FDR ⩽ 0.05).
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